Sunday, July 6, 2025
  • Login
CEO North America
  • Home
  • News
    • Business
    • Entrepreneur
    • Industry
    • Innovation
    • Management & Leadership
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life
    • Art & Culture
    • Food
    • Health
    • Travel
No Result
View All Result
  • Home
  • News
    • Business
    • Entrepreneur
    • Industry
    • Innovation
    • Management & Leadership
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life
    • Art & Culture
    • Food
    • Health
    • Travel
No Result
View All Result
CEO North America
No Result
View All Result

CEO North America > News > FDA Authorizes Novavax’s COVID Vaccine as Booster for Adults

FDA Authorizes Novavax’s COVID Vaccine as Booster for Adults

in News
FDA Authorizes Novavax’s COVID Vaccine as Booster for Adults
Share on LinkedinShare on WhatsApp

The Food and Drug Administration on Wednesday authorized Novavax COVID-19 vaccine as a booster for U.S. adults, including people unable to get updated Omicron boosters.

The authorization of Novavax’s booster could significantly increase its role in U.S. vaccination efforts. The Maryland based biotech’s vaccine was only authorized as a two-dose primary series, limiting its market for those already immunized with Pfizer or Moderna.

The FDA said adults ages 18 and older can receive Novavax as their third dose six months after completion of the primary series of any U.S. authorized Covid vaccine.

“According to CDC data, almost 50 percent of adults who received their primary series have yet to receive their first booster dose. Offering another vaccine choice may help increase COVID-19 booster vaccination rates for these adults,” Novavax CEO Stanley Erck said in a statement Wednesday.

The FDA’s authorization of Novavax’s boosters comes as millions have already received Pfizer’s and Moderna’s new shots that target the omicron BA.5 subvariant and the original strain.

Despite Novavax’s booster being developed against the original strain, the company believes its protein technology is effective against different variants of the virus.

According to the CDC only 35,300 people have received Novavax’s shots as a primary series in the U.S.

U.S. health officials believe Pfizer and Moderna’s updated boosters will provide stronger protection than the first generation of vaccines because they target omicron BA.5, which is causing most infections right now.

Tags: COVID vaccineFDANovavax

Related Posts

Paramount CEO explains why company paid Trump millions in 60 Minutes settlement
News

Paramount CEO explains why company paid Trump millions in 60 Minutes settlement

SAS CEO announces Air France–KLM to become majority owner
News

SAS CEO announces Air France–KLM to become majority owner

- Trump sends letter warning of 70% tariffs
News

Trump sends letter warning of 70% tariffs

Constellation CEO attributes beer sales decline to immigration crackdown
News

Constellation CEO attributes beer sales decline to immigration crackdown

China “strongly opposes” chip controls
News

Trump lifts chip restrictions on China

House on track for deadline after all-nighter
News

House on track for deadline after all-nighter

Hyundai and Kia to adopt Tesla EV chargers
News

Tesla stock rises as company reports steep sales decline

‘Big Beautiful Bill’ Medicaid cuts could leave millions uninsured
News

‘Big Beautiful Bill’ Medicaid cuts could leave millions uninsured

Del Monte Foods files for bankruptsy
News

Del Monte Foods files for bankruptsy

US job availability drops to new two-year low
News

Jobs report shows unexpected increase

No Result
View All Result

Recent Posts

  • What makes the Royal Edinburgh Military Tattoo so special?
  • Beyond the Machine: Why Human-Made Art Matters More in the Age of AI
  • 7 Benefits of High Intensity Interval Training
  • Paramount CEO explains why company paid Trump millions in 60 Minutes settlement
  • SAS CEO announces Air France–KLM to become majority owner

Archives

Categories

  • Art & Culture
  • Business
  • CEO Interviews
  • CEO Life
  • Editor´s Choice
  • Entrepreneur
  • Environment
  • Food
  • Health
  • Highlights
  • Industry
  • Innovation
  • Issues
  • Management & Leadership
  • News
  • Opinion
  • PrimeZone
  • Printed Version
  • Technology
  • Travel
  • Uncategorized

Meta

  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org

  • CONTACT
  • GENERAL ENQUIRIES
  • ADVERTISING
  • MEDIA KIT
  • DIRECTORY
  • TERMS AND CONDITIONS

Advertising –
advertising@ceo-na.com

110 Wall St.,
3rd Floor
New York, NY.
10005
USA
+1 212 432 5800

Avenida Chapultepec 480,
Floor 11
Mexico City
06700
MEXICO

  • News
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life

  • CONTACT
  • GENERAL ENQUIRIES
  • ADVERTISING
  • MEDIA KIT
  • DIRECTORY
  • TERMS AND CONDITIONS

Advertising –
advertising@ceo-na.com

110 Wall St.,
3rd Floor
New York, NY.
10005
USA
+1 212 432 5800

Avenida Chapultepec 480,
Floor 11
Mexico City
06700
MEXICO

CEO North America © 2024 - Sitemap

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Home
  • News
    • Business
    • Entrepreneur
    • Industry
    • Innovation
    • Management & Leadership
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life
    • Art & Culture
    • Food
    • Health
    • Travel

© 2025 JNews - Premium WordPress news & magazine theme by Jegtheme.